Improved mature polypeptide
By developing mature polypeptide β-galactosidase and its mutants with catalytic synthesis of LNT and LNnT activities, the problem of low production efficiency of HMOs in the prior art has been solved, and the efficient synthesis of LNT and LNnT is achieved, which is suitable for a variety of foods and the production of dietary supplements.
Patent Information
- Application Number
- CN202310538564.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-11
- Publication Date
- 2024-11-12
AI Technical Summary
The existing HMOs production technology is difficult to achieve efficient and large-scale production of lactose-N-tetrasaccharides (LNT) and lactose-N-newtetrasaccharides (LNnT), and cannot meet the society's demand for these components.
A mature polypeptide β-galactosidase WP_127489039.1 and its mutant were developed with catalytic synthesis of LNT and LNnT activities. The enzyme activity is improved by improving the amino acid sequence, and related nucleic acid products, enzyme products and preparation methods are provided. and application.
It realizes efficient catalytic synthesis of LNT and LNnT, which is simple, green and suitable for large-scale industrial production, and is suitable for dairy products, baked goods, beverages, dietary supplements and formula foods for special medical purposes.
Smart Images

Figure BDA0004227214770000011 
Figure BDA0004227214770000012 
Figure BDA0004227214770000101
Abstract
Description
Technical Field
[0001] The present invention relates to an improved mature polypeptide and application thereof in synthesizing human milk oligosaccharides, belonging to the technical field of gene and enzyme engineering. Background Art
[0002] Human milk oligosaccharides (HMOs) are a class of natural oligosaccharide mixtures that exist only in breast milk and are also important functional components in breast milk. Studies have found that HMOs play an important role in infants' intestinal health, immune system regulation, physical growth, and brain cognitive development. Among them, lactose-N-tetraose (Lacto-N-tetraose, LNT) is the most abundant HMO in breast milk and is a representative of neutral HMOs. Its chemical formula is shown in Formula 1. It is the core structure common to other long-chain HMOs and many glycolipids. Lactose-N-neotetraose (LNnT) is an isomer of LNT, and its chemical formula is shown in Formula 2. LNT and LNnT are important components of breast milk and have multiple functions. The ratio of the two in breast milk is quite different. The content of LNT is higher, about 8 times that of LNnT (Craft KM, Townsend SD. Synthesis of lacto-N-tetraose. Carbohydr Res. 2017 Feb 22; 440-441: 43-50.).
[0003] For infants who cannot be breastfed, the dosage of LNnT as a food nutrient fortifier in children's formula milk powder, infant formula food, and special medical purpose formula food is 0.2-0.6g / L (based on pure product, based on ready-to-eat state, and the dosage of powdered products is increased according to the multiple of preparation, 2022 Food and Drug Administration draft for comments); the maximum dosage of lactic acid-N-tetraose as infant formula LNT is 1.82g / L (approved by the EU in 2023, produced by Chr. Hansen). Before that, the approved LNT dosage was in the range of 0.6-0.8g / L. Therefore, with the improvement of people's understanding of HMOs and the improvement of production technology, the trend of using higher concentrations of HMOs in infant formula or food has been formed. Although the largest application of HMOs is infant formula products, the great value of HMOs to health is not limited to infants. With the development of the economy, people's demand for breast milk oligosaccharides will gradually increase. .
[0004]
[0005]
[0006] Developing a simple, efficient, low-cost method for large-scale industrial production of HMOs to meet the needs of society is what HMOs research institutions and enterprises are working hard to solve. Chinese patent CN111534503A discloses a method for synthesizing lactose-N-neotetraose (LNnT): using β-galactosidase to catalyze lactose-N-triose and β-lactose to synthesize lactose-N-neotetraose; or using chitinase, HaHex74 protein and β-galactosidase as biological enzymes to catalyze chitin and β-lactose to synthesize lactose-N-triose II and lactose-N-neotetraose.
[0007] In summary, in order to meet social needs, it is necessary to iterate the existing HMOs production technology, and it is imperative to provide efficient and scalable production technology. Summary of the invention
[0008] Purpose of the invention: If the efficient and large-scale production of LNT and LNnT can be achieved simultaneously, it will be beneficial to the rapid proportioning and use of dairy products, baked foods, beverages, dietary supplements, special medical formula foods and infant foods. The purpose of the present invention is to provide mature polypeptides with strong catalytic activity in synthesizing lactose-N-tetraose (LNT) and lactose-N-neotetraose (LNnT), and to use them to catalyze the synthesis of LNT and LNnT. At present, no biosynthetic technology that can synthesize lactose-N-tetraose (LNT) and lacto-N-neotetraose (LNnT) simultaneously has been retrieved.
[0009] In addition, the present application also provides related nucleic acid products, enzyme products, and preparation methods and applications thereof.
[0010] Technical solution:
[0011] A mature polypeptide is β-galactosidase WP_127489039.1, which is derived from Neobacillus mesonae, and its amino acid sequence is shown in SEQ ID NO: 1. In the embodiment, it is referred to as D1, and has the activity of catalyzing the synthesis of lactose-N-tetraose (LNT) and lacto-N-neotetraose (LNnT).
[0012] The β-galactosidase is an enzyme that hydrolyzes β-D-galactosidic bonds to free D-galactose, and is widely present in microorganisms, animals and plants. Its species source can also be: Aspergillus oryzae, Kluyveromyces lactis, Kluyveromyces marxinus, Bacillus subtilis, Bacillus circulans, etc., and further preferred species sources are Bacillus circulans or Bacillus subtilis, etc.
[0013] The applicant has made a series of improvements to the glycoside hydrolase shown in SEQ ID NO: 1, and has improved the activity of synthesizing lactose-N-tetraose (LNT) and lacto-N-neotetraose (LNnT) while retaining the activity of synthesizing lactose-N-tetraose (LNT) and lacto-N-neotetraose (LNnT).
[0014] Specifically, in the first aspect, the present application provides an amino acid sequence as shown in SEQ ID NO:1, which is formed by replacing multiple amino acid residues and has the glycoside hydrolase activity as shown in SEQ ID NO:1; wherein the replacement of the multiple amino acid residues is selected from: the amino acid sequence as shown in SEQ ID NO:1. One or more amino acid residues at positions 182-189, 408-413, 449-454, 481-492, 561-569, 571-573, 591-597, 599-606 and the like in the mature polypeptide are replaced.
[0015] The mature polypeptide mutant has improved catalytic synthesis of LNT and LNnT activity.
[0016] The modification refers to any chemical modification of the polypeptide or its homologous sequence composed of the mature polypeptide, as well as genetic manipulation of the DNA encoding the polypeptide. The modification can be the replacement and / or insertion of one or more (several) amino acid residues.
[0017] The modification of one or more amino acid residues in the mature polypeptide as shown in SEQ ID NO: 1 is preferably selected from one or more of the following mutation schemes:
[0018] The amino acid residues at positions 182-185 are replaced by QPSS to GMNC, the amino acid residue at position 189 is replaced by S to T, and the amino acid residues at positions 408-412 are replaced by QSKKP to YGHYQ, which is called mutant D2, and its amino acid sequence is shown in SEQ ID NO: 2; and / or
[0019] The amino acid residues at positions 408-413 are replaced by QSKKPY to PMNRLT, the amino acid residues at positions 481-482 are replaced by ED to DN, and the amino acid residues at positions 484-492 are replaced by TRGDKVNVT to IKANWNESN, which is called mutant D3, and its amino acid sequence is shown in SEQ ID NO: 3; and / or
[0020] The amino acid residues at positions 450-454 are replaced by YDTTN to KNKET, the amino acid residues at positions 567-569 are replaced by DYV to SLG, and the amino acid residues at positions 571-573 are replaced by WGR to FAK, which is called mutant D4, and its amino acid sequence is shown in SEQ ID NO: 4; and / or
[0021] The amino acid residues at positions 182-184 are replaced by QPS to RAD, the amino acid residue at position 189 is replaced by S to T, the amino acid residues at positions 408-413 are replaced by QSKKPY to PMNRLT, the amino acid residue at position 593 is replaced by I to V, the amino acid residue at position 600 is replaced by I to L, and the amino acid residue at position 606 is replaced by Y to W, which is called mutant D5, and its amino acid sequence is shown in SEQ ID NO: 5; and / or
[0022] The amino acid residues at positions 182-184 are replaced by QPS to RAD, the amino acid residue at position 189 is replaced by S to T, the amino acid residues at positions 408-413 are replaced by QSKKPY to PMNRLT, the amino acid residues at positions 449-453 are replaced by IYDTT to SGHGA, the amino acid residue at position 593 is replaced by I to V, the amino acid residue at position 600 is replaced by I to L, and the amino acid residue at position 606 is replaced by Y to W, which is called mutant D6, and its amino acid sequence is shown in SEQ ID NO: 6; and / or
[0023] The amino acid residues at positions 182-185 are replaced by QPSS to GMNC, the amino acid residue at position 189 is replaced by S to T, the amino acid residues at positions 408-412 are replaced by QSKKP to YGHYQ, the amino acid residues at positions 481-482 are replaced by ED to DN, the amino acid residues at positions 484-492 are replaced by TRGDKVNVT to IKANWNESN, the amino acid residues at positions 567-568 are replaced by DY to SA, the amino acid residue at position 573 is replaced by R to A, the amino acid residue at position 593 is replaced by I to V, the amino acid residues at positions 595-597 are replaced by TGF to DWV, and the amino acid residues at positions 599-606 are replaced by YIGEPTPY to QSLIKYDE, which is called mutant D7, and its amino acid sequence is shown in SEQ ID NO: 7; and / or
[0024] The amino acid residues at positions 182-185 are replaced by QPSS to GMNC, the amino acid residue at position 189 is replaced by S to T, the amino acid residues at positions 408-413 are replaced by QSKKPY to PMNRLT, the amino acid residues at positions 450-454 are replaced by YDTTN to KNKET, the amino acid residues at positions 567-569 are replaced by DYV to SLG, and the amino acid residues at positions 571-573 are replaced by WGR to FAK, which is called mutant D8, and its amino acid sequence is shown in SEQ ID NO: 8; and / or
[0025] The amino acid residues at positions 450-454 are replaced by KNKET from YDTTN, the amino acid residue at position 481 is replaced by A from E, the amino acid residue at position 484 is replaced by F from T, the amino acid residues at positions 486-492 are replaced by FGNGSGG from GDKVNVT, the amino acid residues at positions 567-569 are replaced by DYV from SLG, the amino acid residues at positions 571-573 are replaced by WGR from FAK, the amino acid residue at position 593 is replaced by I from V, the amino acid residues at positions 595-597 are replaced by TGF from DWV, and the amino acid residues at positions 599-606 are replaced by YIGEPTPY from QSLIKYDE, which is called mutant D9, and its amino acid sequence is shown in SEQ ID NO:9; and / or
[0026] The amino acid residues at positions 182-184 are replaced by QPS to RAD, the amino acid residue at position 189 is replaced by S to T, the amino acid residues at positions 449-453 are replaced by IYDTT to SGHGA, the amino acid residue at position 481 is replaced by E to A, the amino acid residue at position 484 is replaced by T to F, the amino acid residues at positions 486-492 are replaced by GDKVNVT to FGNGSGG, the amino acid residues at positions 567-568 are replaced by DY to SA, the amino acid residue at position 573 is replaced by R to A, the amino acid residue at position 593 is replaced by I to V, the amino acid residues at positions 595-597 are replaced by TGF to DWV, and the amino acid residues at positions 599-606 are replaced by YIGEPTPY to QSLIKYDE, which is called mutant D10, and its amino acid sequence is shown in SEQ ID NO: 10; and / or
[0027] The amino acid residues at positions 182-185 were replaced by QPSS to GMNC, the amino acid residue at position 189 was replaced by S to T, the amino acid residues at positions 408-413 were replaced by QSKKPY to PMNRLT, the amino acid residues at positions 449-453 were replaced by IYDTT to SGHGA, the amino acid residue at position 481 was replaced by E to A, the amino acid residue at position 484 was replaced by T to F, the amino acid residues at positions 486-492 were replaced by GDKVNVT to FGNGSGG, the amino acid residues at positions 567-568 were replaced by DY to SA, the amino acid residue at position 573 was replaced by R to A, the amino acid residue at position 593 was replaced by I to V, the amino acid residues at positions 595-597 were replaced by TGF to DWV, the amino acid residues at positions 599-606 were replaced by
[0028] YIGEPTPY was replaced by QSLIKYDE, which was named mutant D11, and its amino acid sequence is shown in SEQ ID NO:11.
[0029] Preferably, the mature polypeptide and / or mature polypeptide mutant comprises a polypeptide having an amino acid sequence with at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 1 and / or SEQ ID NO: 2 and / or SEQ ID NO: 3 and / or SEQ ID NO: 4 and / or SEQ ID NO: 5 and / or SEQ ID NO: 6 and / or SEQ ID NO: 7 and / or SEQ ID NO: 8 and / or SEQ ID NO: 9 and / or SEQ ID NO: 10 and / or SEQ ID NO: 11, and has an improved ability to catalyze the synthesis of lactose-N-tetraose (LNT) and lactose-N-neotetraose (LNnT).
[0030] In a second aspect, the present application provides a polynucleotide encoding the polypeptide as described in the first aspect above.
[0031] In a third aspect, the present application provides a nucleic acid construct comprising the polynucleotide as described in the second aspect above, and one or more regulatory sequences operably linked thereto, wherein the regulatory sequences can guide the production of the polypeptide in a suitable expression host.
[0032] In a fourth aspect, the present application provides an expression vector comprising the polynucleotide as described in the second aspect above, or comprising the nucleic acid construct as described in the third aspect above.
[0033] In a fifth aspect, the present application provides a transformed host cell, into which the nucleic acid construct as described in the third aspect or the expression vector as described in the fourth aspect is transformed.
[0034] In a sixth aspect, the present application also provides an enzyme agent or enzyme composition, which comprises the mature polypeptide described in SEQ ID NO: 1 or a mutant thereof.
[0035] Preferably, the composition contains one or more polypeptides having an amino acid sequence having at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 1 and / or SEQ ID NO: 2 and / or SEQ ID NO: 3 and / or SEQ ID NO: 4 and / or SEQ ID NO: 5 and / or SEQ ID NO: 6 and / or SEQ ID NO: 7 and / or SEQ ID NO: 8 and / or SEQ ID NO: 9 and / or SEQ ID NO: 10 and / or SEQ ID NO: 11.
[0036] In a seventh aspect, the present application further provides a method for expressing the mature polypeptide and / or its mutants shown in SEQ ID NO: 1, comprising the following steps:
[0037] (a) culturing a host cell under conditions suitable for expressing the mature polypeptide shown in SEQ ID NO: 1 and / or its mutants; and
[0038] (b) recovering the mature polypeptide and / or its mutants shown in SEQ ID NO: 1.
[0039] In the step (a), preferably, a host cell comprising a nucleic acid construct comprising a nucleotide sequence encoding the polypeptide is cultured under conditions conducive to the production of the polypeptide.
[0040] In the step (a), preferably, a recombinant plasmid encoding the mature polypeptide shown in SEQ ID NO: 1 and / or its mutant gene is first constructed, and then introduced into a host cell;
[0041] The host cell in step (a) preferably comprises a recombinant engineered strain of the host cell.
[0042] The step (a) preferably comprises: firstly introducing a nucleic acid construct or a recombinant expression vector encoding the mature polypeptide shown in SEQ ID NO:1 or a mutant thereof into a host cell to construct an engineered host cell expressing the mature polypeptide shown in SEQ ID NO:1 or a mutant thereof; then, culturing the engineered host cell and inducing it to express the mature polypeptide shown in SEQ ID NO:1 or a mutant thereof.
[0043] The step (a) preferably comprises: firstly designing mutation primers for site-directed mutagenesis according to the determined mutation site, and performing site-directed mutagenesis using a vector carrying the β-galactosidase gene as a template; constructing a plasmid vector containing a gene encoding the mature polypeptide shown in SEQ ID NO: 1 or a mutant thereof; and then transforming the plasmid into a host cell.
[0044] The step (b) preferably further comprises separating and purifying the mature polypeptide and / or its mutants shown in SEQ ID NO: 1.
[0045] The step (b) preferably comprises: after the expression is completed, the cultured cells are broken to obtain a crude enzyme solution containing the mature polypeptide shown in SEQ ID NO: 1 or its mutant; optionally, it also comprises the step of separating and purifying the mature polypeptide shown in SEQ ID NO: 1 or its mutant.
[0046] The step (b) preferably comprises: selecting positive clones for fermentation culture, centrifuging, and the supernatant is a crude enzyme solution of the mature polypeptide shown in SEQ ID NO: 1 or its mutant.
[0047] Preferably, the separation and purification step can be performed by conventional protein purification methods, such as ion exchange chromatography, hydrophobic chromatography, gel filtration chromatography, salting out, etc. or a combination thereof; further preferably, purification can be performed by Ni column affinity chromatography.
[0048] Preferably, in the method for expressing the mature polypeptide shown in SEQ ID NO: 1 and / or its mutants, the host cell is selected from yeast cells, bacterial cells or molds.
[0049] The host cell preferably includes: Bacillus and Escherichia; more preferably, includes Escherichia coli, Escherichia hermanii, Escherichia fergusonii, Bacillus mycoides, Bacillus cereus, Bacillus licheniformis, Bacillus brevis, Bacillus circulans or Bacillus subtilis;
[0050] Further preferably, the host cell is Bacillus circulans or Bacillus subtilis
[0051] (Bacillus subtilis) or Bacillus licheniformis.
[0052] The mold preferably includes: Aspergillus and Trichoderma; further preferably, it is Trichoderma viride, Trichoderma reesei, Aspergillus oryzae, Aspergillus fumigatu, Aspergillus niger, or Aspergillus flavus cells; further preferably, the host cell is Aspergillus oryzae cells.
[0053] The yeast cells preferably include: cells of the genera Candida, Hansenula, Kluyveromyces, Pichia, Saccharomyces, Schizosaccharomyces, or Yarrowia; further preferred are cells of Saccharomyces cerevisiae, Kluyveromyces lactis, Kluyveromyces marxinus, Yarrowia lipolytica, Rhodotorula graminis, Saccharomyces pastorianus, etc.; further preferred are cells of Saccharomyces cerevisiae, Kluyveromyces lactis, and Kluyveromyces marxinus.
[0054] The method for expressing the mature polypeptide shown in SEQ ID NO: 1 or its mutant, preferably, the host cell includes a wild strain isolated from nature, or a mutant strain after physical and chemical mutagenesis, or an engineered bacterium after genetic engineering.
[0055] Host cells are cultivated in a nutrient medium suitable for producing mature polypeptide and / or mature polypeptide mutants using methods known in the art. For example, it is possible to culture by shaking bottles, or in a suitable medium and under conditions allowing mature polypeptide and / or mature polypeptide mutants to express and / or separate, in a laboratory or industrial fermentor tank, carry out small-scale or large-scale fermentation (including continuous fermentation, batch fermentation, batch-fed fermentation or solid-state fermentation) to cultivate cells. Cultivation is to use procedures known in the art, and occurs in a suitable nutrient medium, and the medium comprises carbon and nitrogen sources and inorganic salts. Suitable medium can be purchased through commercial channels, or prepared according to disclosed composition.
[0056] The mature polypeptide or mutant thereof shown in SEQ ID NO: 1 can be recovered using methods known in the art. For example, the variant can be recovered from the nutrient medium by a variety of conventional procedures, including but not limited to collection, centrifugation, filtration, extraction, spray drying, evaporation or precipitation.
[0057] The mature polypeptide and / or its mutant can be purified by various procedures known in the art to obtain substantially pure mature polypeptide and / or its mutant, including but not limited to chromatography (e.g., ion exchange chromatography, affinity chromatography, hydrophobic interaction chromatography, gel filtration chromatography), electrophoresis procedures (e.g., preparative isoelectric focusing), differential solubility methods (e.g., ammonium sulfate precipitation), SDS-PAGE, salting out, etc. or a combination thereof for separation or purification. Further preferably, purification can also be carried out by Ni column affinity chromatography.
[0058] In an eighth aspect, the present application provides a synthetic method for producing LNT and LNnT, comprising: using the mature polypeptide shown in SEQ ID NO: 1 or a mutant thereof as a catalyst to catalyze the reaction of lactose and lactose-N-triose (Lacto-N-triose, LNTII) to produce LNT and LNnT.
[0059] In some embodiments, the use of the mature polypeptide shown in SEQ ID NO: 1 or its mutants, or a combination thereof, in the production of LNT and LNnT is described.
[0060] The application preferably comprises the steps of generating LNT and LNnT.
[0061] In the application, preferably, the reaction substrate is a carbohydrate of lactose or its derivatives.
[0062] In the application, preferably, the reaction substrates are lactose and lactose-N-triose (Lacto-N-triose, LNTII).
[0063] In the application, preferably, the reaction solvent is an aqueous solvent or a solution containing solids.
[0064] In the application, preferably, the culture fluid containing the mature polypeptide and / or its mutant can be directly used; preferably, the mature polypeptide and / or its mutant is purified and used as a catalyst.
[0065] For the application, preferably, process parameters such as temperature, enzyme addition amount, reaction time, pH and the like can be studied or selected according to the method disclosed in the present invention.
[0066] definition:
[0067] The terms "mature polypeptide" and "mature polypeptide mutant" refer to any post-translational sequence or sequence modification, such as a known sequence, its N-terminal processing, truncation and / or C-terminal truncation. In one aspect, "mature polypeptide" and "mature polypeptide mutant" are both "mature polypeptides", and the mature polypeptides and mutants thereof of the present invention include proteins shown in SEQ ID NO: 1-11.
[0068] The term "host cell" refers to any cell type that is susceptible to transformation, transfection, transduction, etc. with an expression vector. The term "host cell" encompasses any progeny of a parent cell that is not identical to the parent cell due to substitutions that occur during replication.
[0069] The term "nucleic acid construct" refers to an artificially constructed nucleic acid fragment, particularly a DNA fragment, which is intended to be "transplanted" into a target cell (e.g., a bacterial cell) to modify the expression of a genomic gene or to express a gene / coding DNA sequence that may be included in the construct.
[0070] Beneficial Effects
[0071] The present invention provides a series of novel mature polypeptide mutants and expression methods, which retain and improve the activity of the mature polypeptide shown in SEQ ID NO: 1 in catalyzing the synthesis of LNT and LNnT. The method of the present invention for catalyzing the synthesis of LNT and LNnT by the mature polypeptide mutants is simple, green and efficient.
[0072] The present invention provides for the first time a mature polypeptide and a mutant thereof having the activity of catalyzing and synthesizing LNT and LNnT. The obtained product can be eaten directly or after being mixed with other ingredients as required. BRIEF DESCRIPTION OF THE DRAWINGS
[0073] Figure 1 .LNT, LNnT mass spectrum DETAILED DESCRIPTION
[0074] The following provides methods for expressing the mature polypeptide and / or its mutants of the present invention, as well as examples of their application.
[0075] The experimental methods used in the following examples are conventional methods unless otherwise specified; all materials, reagents, etc., are commercially available unless otherwise specified.
[0076] The present invention is further described in detail below through examples. It should be understood that the specific implementation methods described herein are only used to explain the present invention and are not used to limit the present invention. Modifications or replacements to the details and forms of the technical solution without departing from the structural concept and scope of use of the present invention all fall within the protection scope of the present invention.
[0077] Unless otherwise defined, all technical terms and scientific terms used in this specification have the same meanings as those commonly understood by those skilled in the art. In general, the nomenclature used in this specification and the experimental methods described below are well known and commonly used in the art.
[0078] In the following examples and test examples, the products obtained from the catalytic reaction of the mature polypeptide and / or the mature polypeptide mutant were analyzed and identified using HPLC analysis method and ion chromatography.
[0079] HPLC analysis conditions are as follows: using a 4.6×250 mm, 5 μm Asahipak NH2P-504E amino column, isocratic elution with 65% acetonitrile aqueous solution as the mobile phase; flow rate is 0.5 mL / min, column temperature is 30°C, injection volume is 10 μL, UV detector, detection wavelength is 195 nm.
[0080] The ion chromatography analysis conditions were as follows: chromatographic column: MetroSep Carb2 (4.0 mm × 250 mm), eluent: 140 mM NaOH + 20 mM NaAc, isocratic elution, flow rate: 0.500 mL / min, amperometric detector, column temperature 40 °C, injection volume 20 μL, running time 50 min.
[0081] Lactose-N-triose (LNTⅡ), lactose-N-tetraose (LNT), and lactose-N-neotetraose (LNnT) standards were produced by ELICITYL, France.
[0082] It should be noted that the terms used here are only for describing specific embodiments and are not intended to limit the exemplary embodiments according to the present invention. In addition, it should also be understood that when the terms "comprising" and / or "including" are used in this specification, it indicates the presence of features, steps, operations and / or combinations thereof. It should be understood that the scope of protection of the present invention is not limited to the specific embodiments described below; it should also be understood that the terms used in the embodiments of the present invention are to describe specific embodiments, rather than to limit the scope of protection of the present invention. If the experimental methods of specific conditions are not indicated in the following specific embodiments, the conventional methods and conditions of molecular biology within the art are generally followed, and such techniques and conditions are fully explained in the literature. See, for example, Sambrook et al., the techniques and conditions described in "Molecular Cloning: A Laboratory Manual", or according to the conditions recommended by the manufacturer.
[0083] Example 1. Expression of mature polypeptide and / or mature polypeptide mutant in E. coli
[0084] By using protein engineering technology and high-throughput screening, the glycosidase with the amino acid sequence shown in SEQ ID NO: 1 was modified to obtain a series of mutants with significantly improved efficiency in catalyzing the synthesis of LNT and LNnT. The specific steps are as follows:
[0085] Through codon optimization and DNA synthesis, the gene corresponding to the mature polypeptide and / or its mutant shown in SEQ ID NO:1 was obtained. Referring to the method of the Molecular Cloning Experiment Guide, the pET32a-BgaD-D1-11 series of plasmids / or recombinant plasmid series were constructed, as shown in Table 1. The above recombinant plasmids were transformed into Escherichia coli BL21 (DE3) according to the following steps: Take the prepared Escherichia coli BL21 (DE3) competent cells, place them on ice for 30 minutes to melt, take 100 μL of competent cells and mix them with 10 μL of pET32a-BgaD-D1-11 plasmid / or recombinant plasmid (concentration 50 ng / μL), let it stand for 30 minutes, place it in a 42°C water bath for heat shock for 45 seconds, then immediately cool it in an ice bath for 2 minutes, add 700 μL of fresh LB medium (LB medium: peptone 1.0%, yeast extract 0.5%, NaCl 1.0%, 1.5% agar powder added to the plate), and resuscitated and cultured at 37°C and 220rpm for 1h, then 100μL of the bacterial solution was spread on an LB plate containing ampicillin (100μg / mL), and cultured in a 37°C constant temperature incubator for 12h, and a single colony was picked for PCR experiment. The primer sequences are shown in Table 1, and positive transformants were screened. Further, after culturing the correct transformants, their plasmids were extracted, and PCR amplification, double enzyme digestion, and gene sequencing were used to verify whether the pET32a-BgaD-D1-11 series plasmids / or recombinant plasmids were successfully introduced into E. coli.
[0086] Then, the correct transformant was inoculated into LB liquid medium and cultured on a shaker at 37°C and 200 rpm for 12 h to obtain seed solution. The seed solution was then inoculated into fresh LB medium at a 1% (v / v) inoculation rate and cultured at 37°C with shaking until OD 600 The expression of the expression vector was 0.8, and the cell was induced by isopropyl-β-D-thiogalactopyranoside (IPTG), with a final concentration of 0.05mmol / L of IPTG, at 16℃ for 12h, at a speed of 200rpm. After induction of expression, the fermentation broth was centrifuged at 6000rpm for 10min at 4℃ to collect the cells. The cells were resuspended in 20mM imidazole pH7.4 PBS buffer, and ultrasonicated for 20min at a frequency of plus on 5s / off 5s to break the cells; the liquid after breaking was centrifuged at 12000×g, 4℃ for 30min to remove cell debris and collect the supernatant.
[0087] The mature polypeptide or its mutant shown in SEQ ID NO: 1 was purified by nickel column affinity chromatography, and the process was as follows: deionized water was added to the nickel column to the top of the column, and after natural elution, it was eluted with 5 volumes of Binding buffer; the crude enzyme solution filtered by 0.45 μm filter membrane was then loaded onto the column, and the sample was fully combined with the nickel column at a flow rate of 1.5 mL / min. After the sample was dried, it was continuously gradient eluted with 5 times the column volume of Washing buffer to remove impurities, and finally the target protein was eluted with 5 times Elution buffer, and the eluate was collected. Then SDS-PAGE was used to analyze the expression of the target protein. After induction, the genetically engineered bacteria had obvious specific expression bands, and the molecular weight of the band was basically consistent with the expected molecular weight of 90.77 kDa, and the mature polypeptide and / or its mutant shown in SEQ ID NO: 1 were obtained.
[0088] Table 1. Mature polypeptide and mutants thereof shown in SEQ ID NO: 1 and corresponding recombinant plasmids and primers
[0089]
[0090]
[0091]
[0092]
[0093] Table 2. Correspondence between recombinant plasmids and mutants
[0094] Mature polypeptide and / or mutant Plasmid / or recombinant plasmid Mature polypeptide / or mutant sequence number D1 pET32a-BgaD-D1 SEQ ID NO:1 D2 pET32a-BgaD-D2 SEQ ID NO:2 D3 pET32a-BgaD-D3 SEQ ID NO:3 D4 pET32a-BgaD-D4 SEQ ID NO:4 D5 pET32a-BgaD-D5 SEQ ID NO:5 D6 pET32a-BgaD-D6 SEQ ID NO:6 D7 pET32a-BgaD-D7 SEQ ID NO:7 D8 pET32a-BgaD-D8 SEQ ID NO:8 D9 pET32a-BgaD-D9 SEQ ID NO:9 D10 pET32a-BgaD-D10 SEQ ID NO:10 D11 pET32a-BgaD-D11 SEQ ID NO:11
[0095] Example 2. Study on the catalytic synthesis of the mature polypeptide shown in SEQ ID NO: 1 and its mutants
[0096] Study on the synthesis of lactose-N-tetraose (LNT) and lactose-N-neotetraose (LNnT) catalyzed by the mature polypeptide shown in SEQ ID NO: 1 and its mutants (after purification).
[0097] The purified mature polypeptide shown in SEQ ID NO: 1 obtained in Example 1 or its mutant was used for enzyme catalysis, specifically: 128 mM lactose, 20 mM lactose-N-triose (Lacto-N-trioseⅡ, LNTII), the mature polypeptide (D1) / or its mutant (D2-11) described in Table 3, 10 mM MgCl2, 100 mM phosphate buffer (pH 8) were added to 5 mL, mixed, reacted at 40°C for a reaction time as described in Table 3, the reaction was terminated, and purified by a gel column method.
[0098] Identification of catalytic synthesis products:
[0099] High performance liquid chromatography (HPLC), LC-MS analysis methods, and ion chromatography were used to analyze the products of the catalytic reaction of lactose-N-tetraose (LNT), lactose-N-neotetraose (LNnT) standards and the mature polypeptide shown in SEQ ID NO: 1, or its mutants.
[0100] The HPLC analysis conditions were as shown above, and the analysis results showed:
[0101] (1) The peak time rt of LNT and LNnT standards is 15.800 min.
[0102] (2) In this example, the reaction solution catalyzed by the mature polypeptide shown in SEQ ID NO: 1 or its mutants showed a strong absorption peak at around 15.800 min at a wavelength of 195 nm, which was consistent with the peak time of LNT and LNnT standards, indicating that lactose-N-tetraose (LNT) and / or lactose-N-neotetraose LNnT may have been synthesized in the reaction solution.
[0103] LC-MS analysis
[0104] The product at rt=15.800 min in the HPLC spectrum was subjected to LC-MS analysis.
[0105] The mass spectra of the lactose-N-neotetraose (LNnT) standard are the same as those of the lactose-N-tetraose (LNT) standard.
[0106] As attached Figure 1 As shown, the molecular weight of 708.2567 should be LNnT / LNT+H; the molecular weight of 730.2393 should be LNnT / LNT+Na. The mass spectrometry results can be retrieved to obtain the following results: Compound CID:440993, Chemical Formula:C 26 H 45 NO 21 , Extract Mass:707.63.
[0107] In this example, the mass spectrometry results of the reaction solution of the mature polypeptide shown in SEQ ID NO: 1 or its mutant at rt = 15.800 min were consistent with those of the attached Figure 1 Therefore, it is speculated that the mature polypeptide shown in SEQ ID NO: 1 or its mutants synthesize a substance with a molecular weight of about 707, which may be lactose-N-neotetraose (LNnT) and / or lactose-N-tetraose (LNT).
[0108] The results of ion chromatography analysis showed:
[0109] (1) The peak time of lactose-N-neotetraose (LNnT) standard is 26.99 min; the peak time of lactose-N-tetraose (LNT) standard is 30.92 min.
[0110] (2) In this example, the substance with rt=15.800 min in the reaction solution of the mature polypeptide shown in SEQ ID NO: 1 or its mutant was respectively intercepted and analyzed by ion chromatography, and the following results were obtained:
[0111] in conclusion
[0112] As shown by the above HPLC, LC-MS and ion chromatography analysis results, the catalytic reaction using lactose and lactose-N-triose (Lacto-N-trioseⅡ) as substrates is catalyzed by the mature polypeptide shown in SEQ ID NO:1 or its mutants.
[0113] The catalytic reactions synthesized lactose-N-neotetraose (LNnT) and lactose-N-tetraose (LNT).
[0114] The yield of lactose-N-tetraose (LNT) and / or lactose-N-neotetraose (LNnT) in the reaction solution was determined by ion chromatography, and the results are recorded in Table 3.
[0115] Table 3. Studies on the synthesis of LNT and LNnT catalyzed by the mature polypeptide shown in SEQ ID NO: 1 or its mutants
[0116]
[0117]
[0118] Table 3 Data Description:
[0119] (1) Both the mature polypeptide D1 and the mature polypeptide mutants D2-D11 have the activity of catalyzing the synthesis of LNT and LNnT.
[0120] (2) The mature polypeptide mutants D2, D3, D5, D6, D7, D9, D10, and D11 have higher catalytic activity in the synthesis of LNT and LNnT.
[0121] Example 3. Expression of mature polypeptide mutants D3 and D10 in Kluyveromyces lactis
[0122] The construction method of recombinant plasmids pKLAC1-D3 and pKLAC1-D10 is as follows:
[0123] According to the gene sequence of mature polypeptide mutant D3 or D10, PCR amplification was performed. PCR reaction system 50μL: DNA template 1μL, 2×Phanta Max Buffer 25μL, 10pmol / μL dNTP Mix 1μL, 10pmol / μL forward and reverse primers 2μL each, 1U / μL Phanta Max Super-Fidelity DNA Polymerase DNA polymerase 1μL, add ddH2O to 50μL. PCR reaction program: 95℃ 3min; 95℃ 15s, 60℃ 15s, 72℃ 1.5min, 33 cycles; 72℃ 5min; 4℃ storage. The PCR fragment and plasmid fragment were double-digested with restriction endonucleases XmajI and NotI, respectively, and then ligated with ligationhigh ligase, transformed into Escherichia coli DH5ɑ, and the recombinant plasmid pKLAC1-D3 or pKLAC1-D10 was obtained after screening and identification.
[0124] Then, the KLAC1-D3 or KLAC1-D10 expression cassette was amplified. According to the sequence of the pklac1 plasmid, primers were designed for PCR amplification. 50 μL of PCR reaction system: 1 μL (about 50 ng) of DNA template (pklac1-BgaD-D3 or pklac1-BgaD-D10), 25 μL of 2×Phanta Max Buffer, 1 μL of 10 pmol / μL dNTP Mix, 2 μL of 10 pmol / μL forward and reverse primers, 1 μL of 1U / μL Phanta Max Super-Fidelity DNA Polymerase, and ddH2O was added to 50 μL. The PCR reaction program was set up as above. After agarose gel electrophoresis, the gel was cut and recovered to obtain the KLAC1-D3 or KLAC1-D10 expression cassette.
[0125] Afterwards, the KLAC1-D3 or KLAC1-D10 expression cassette was transformed into Kluyveromyces lactis CICC1773. The specific operation was as follows: freshly cultured Kluyveromyces lactis colonies were picked into 1 mL YPD medium, placed in a constant temperature oscillator, and cultured at 30°C and 250 rpm for 12-14 h; the initial inoculation OD was transferred to 50 mL fresh YPD medium, and cultured at 30°C and 200 rpm for 3-4 h until the OD was 0.8-1; the bacterial culture was placed on ice for 5-10 min, and at the same time, 25 μL salmon sperm DNA (2 mg / mL) was placed in a PCR instrument at 95°C for 10 min and quickly cooled in an ice water bath, and placed on ice for use; the expression cassette solution to be transformed was prepared, a total amount of 5-10 μg was added to each tube, and the solution was filled to 50 μL with sterilized ddH2O. After standing on ice, centrifuge the culture solution at 4°C, 5000×g for 5 min, discard the supernatant, and collect the bacteria; resuspend the bacteria with sterilized ddH2O, centrifuge at 4°C, 5000×g for 5 min, discard the supernatant, collect the bacteria, and repeat once; add 1mL 0.1M LiCl solution to resuspend the bacteria, transfer to a new 1.5mL centrifuge tube, centrifuge at 4°C, 13000×g for 15s, and discard the supernatant; add 400μL of 0.1M LiCl solution to resuspend the bacteria, divide into 50μL per tube, centrifuge at 4°C, 13000×g for 15s, discard the supernatant, and place on ice for use; add 240μL of 50% PEG3350 solution and 1M 36μL of LiCl solution, 25μL of pre-treated salmon sperm DNA solution, 50μL of expression cassette solution to be transformed, vortex vigorously to mix until the bacteria are completely distributed (about 5min); the fully mixed system is placed in a 30℃ water bath for 30min; placed in a 42℃ constant temperature water bath, heat shock for 25min; at room temperature, centrifuge at 8000×g for 2min to collect the bacteria, resuspend the bacteria with 1mL YPD, and culture on a 30℃ shaker for 1~4h. Take 25~135μL of bacterial solution and apply it to the culture plate containing G418 resistance; place the plate in a 30℃ constant temperature incubator, invert and culture for 2-3 days, and pick the transformant to verify whether the expression cassette has been successfully transferred.
[0126] The shake flask fermentation was performed as follows: 1) Preparation of primary strain: a single colony of the above yeast genetically engineered strain was cultured overnight in 10 mL YGD liquid medium at 30°C and 200 rpm. The resulting strain was the primary strain. 2) Preparation of secondary strain: the primary strain was inoculated into 1 L YGD liquid medium and cultured at 30°C and 200 rpm until OD 6003) The YGD medium was centrifuged to obtain the crude enzyme solution of the target protein, and the protein was purified according to the method in Example 1. The obtained proteins were mature polypeptide mutants KL-D3 and KL-D10, and their amino acid sequences were shown in SEQ ID NO: 3 and SEQ ID NO: 10, respectively.
[0127] KL-D3 and KL-D10 were used for enzyme catalysis, and their abilities of catalyzing the synthesis of LNT and LNnT were measured.
[0128] Specifically, 128 mM lactose, 20 mM lactose-N-triose (Lacto-N-trioseⅡ, LNTII), 0.3 mg / mL mature polypeptide mutant KL-D3 or KL-D10, 10 mmol / L MgCl2, 100 mM phosphate buffer (pH 8) were fixed to 5 mL, mixed, reacted at 40°C for 24 hours, terminated the reaction, and purified by gel column method. The results are recorded in Table 4.
[0129] Table 4
[0130]
[0131] Example 4. Expression of mature polypeptide mutants D3 and D10 in Bacillus subtilis
[0132] According to the gene sequence of the mature polypeptide mutant D3 or D10, PCR amplification was performed. The PCR reaction system was 50 μL, and the specific operation was the same as in Example 2. PCR reaction program: 95°C for 3 min; 95°C for 15 s, 58°C for 15 s, 72°C for 2.5 min, 30 cycles; 72°C for 5 min; stored at 4°C. After double digestion of the PCR fragment and plasmid pEB03 with restriction endonucleases EcoR I and Hind III, they were ligated with T4 ligase and transformed into Escherichia coli DH5α, and the recombinant plasmid was obtained after screening and identification.
[0133] The transformation method of the recombinant plasmid in Bacillus subtilis 168 is as follows: take a full loop of Bacillus subtilis glycerol bacteria and streak it on LB plate (LB medium: peptone 1.0%, yeast extract 0.5%, NaCl 1.0%, plate plus 1.5% agar powder), and culture it in a 37°C incubator overnight. Pick a single colony to 1mL LB medium, culture it at 37°C, 200rpm overnight, take 200μL culture solution and transfer it to 200mL growth medium (growth medium: LB medium plus 0.5M sorbitol), and culture it at 37°C, 200rpm until OD 600Reach 0.85-0.95, ice bath for 10min, 4°C, 5000rpm centrifugation for 5min, then wash 4 times with pre-cooled electrotransfer medium (electrotransfer medium: LB medium with 0.5M sorbitol, 10% glycerol), and finally resuspend with 2mL pre-cooled electrotransfer medium. The treated bacterial solution is divided into 80μL per tube, 1μL plasmid is added, transferred to a pre-cooled electrotransfer cup, placed on ice for 1-1.5min, and then electrotransformed using an electrotransfer instrument. The electrotransformation parameters are set as follows: voltage 2000V, resistance 200Ω, followed by an ice bath for 2min, and then 1mL recovery medium (recovery medium: LB medium with 0.5M sorbitol, 0.38M mannitol) is added and cultured at 37°C, 200rpm for 90min, and the bacterial solution is coated on a chloramphenicol (5μg / mL) LB plate, and the transformant is picked to obtain the target Bacillus subtilis genetic engineering strain.
[0134] Pick a positive transformation colony from the LB plate containing 5μg / mL chloramphenicol and inoculate it into 20mL seed medium (0.5% yeast extract, 0.5% tryptone, 1% glucose, 1.8% K2HPO4, 5μg / mL chloramphenicol) and culture it at 37℃ and 220rpm for 8h. Take 2.5mL and inoculate it into 50mL fermentation medium (1.0% tryptone, 0.5% yeast extract, NaCl
[0135] 1.0%), 34°C, 250rpm shaking culture for 60h, and the supernatant was subjected to SDS-PAGE electrophoresis. The expression of the target protein was analyzed by SDS-PAGE, and mature polypeptide mutants BS-D3 and BS-D10 were obtained, and their amino acid sequences were shown in SEQ ID NO:3 and SEQ ID NO:10, respectively.
[0136] BS-D3 and BS-D10 were used for enzyme catalysis, and their abilities of BS-D3 and BS-D10 in catalyzing the synthesis of LNT and LNnT were measured.
[0137] Specifically, 128 mM lactose, 20 mM lactose-N-triose (Lacto-N-trioseⅡ, LNTII), 0.3 mg / mL mature polypeptide mutant BS-D3 or BS-D10, 10 mmol / L MgCl2, 100 mM phosphate buffer (pH 8) were fixed to 5 mL, mixed, reacted at 40°C for 24 hours, terminated the reaction, and purified by gel column method. The results are recorded in Table 5.
[0138] Table 5
[0139]
[0140]
[0141] Example 5. Expression of mature polypeptide mutants D3 and D10 in Aspergillus oryzae
[0142] In this experiment, genomic DNA was extracted from Aspergillus oryzae, and the Aspergillus oryzae genomic DNA was used as a template to amplify the Aspergillus oryzae amylase promoter and glycosidase terminator. The promoter, terminator and expression vector backbone pCAMBIA1304 were digested and connected respectively, and the promoter PamyB and terminator TagdA were connected to the corresponding restriction sites to construct the Aspergillus oryzae reading frame to obtain the plasmid pCAMBIA001. The genes of the mature polypeptide mutants D3 and D10 and the plasmid pCAMBIA001 were double-digested with SalI and SpeI, respectively, and the two sequences digested with the same restriction endonuclease were connected. The connected products were transformed into Escherichia coli competent cells DH5α, and the positive clones were screened and expanded for culture. The plasmids pCAMBIA002 and pCAMBIA003 were extracted, and the recombinant plasmids were sequenced for verification. The sequencing results showed that the target gene was correct.
[0143] Preparation of competent Agrobacterium tumefaciens EHA105: 1) Take Agrobacterium tumefaciens EHA105 activated on solid YEB plate and inoculate it into 20mL liquid YEB medium to which rifampicin antibiotics have been added. Shake and culture at 28°C, 180rpm for 24h. 2) Inoculate Agrobacterium tumefaciens into 50mL liquid YEB medium supplemented with rifampicin at a 1% inoculum amount and shake and culture at 28°C, 180rpm until OD 600 3) Place 50 mL of bacterial solution on ice for 30 min, centrifuge at 5000 rpm for 10 min at 4°C, and discard the supernatant. 4) Add 10 mL of pre-cooled 0.1 M CaCl2 solution, resuspend the bacteria, place on ice for 30 min; centrifuge at 5000 rpm for 10 min at 4°C, and discard the supernatant. 5) Add 2 mL of pre-cooled 0.1 M CaCl2 and 2 mL of glycerol, resuspend the EHA105 cells, and aliquot into 135 μL portions for use, and store in an ultra-low temperature refrigerator at -70°C for later use.
[0144] The pCAMBIA002 and pCAMBIA003 plasmids were transformed into competent EHA105 by freeze-thaw method: 1) Thaw the competent EHA105 of Agrobacterium tumefaciens on ice, add 10 μL of recombinant plasmids pCAMBIA002 and pCAMBIA003, mix well, and place on ice for 30 minutes. 2) Quickly place in liquid nitrogen for cold stimulation for 5 minutes, and immediately place in a 28°C constant temperature water bath and incubate for 5 minutes. 3) Place on ice for 5 minutes. 4) Add 400 μL of YEB liquid culture medium without rifampicin to the mixture, and culture at 28°C with shaking at 180 rpm for 2 hours. 5) Take 200 mL of bacterial solution and spread on solid YEB plates containing rifampicin and kanamycin, and culture at 28°C upside down for 48 hours to observe the formation of colonies. 6) Pick a single colony and place it in 20 mL of YEB liquid medium containing rifampicin and kanamycin, and shake and incubate at 28°C and 180 rpm for 48 hours. Identify and screen positive clones using colony PCR. Extract plasmid DNA from positive clones and perform plasmid PCR detection.
[0145] Transformation of Aspergillus oryzae by Agrobacterium tumefaciens-mediated expression vector: 1) Inoculate the EHA105 bacterial solution containing different expression vectors into liquid LB medium supplemented with rifampicin and kanamycin, and culture at 28°C and 180rpm for 24h. 2) Take 2mL of bacterial solution and add it to a mixed medium consisting of 10mL of liquid LB medium and 10mL of basal medium, and culture at 28°C and 180rpm for 48h. 3) Take 2mL of bacterial solution and add it to 20mL of induction medium, and culture at 28°C and 180rpm until OD600 is 0.8, and then co-culture with Aspergillus oryzae ATCC 10124. 4) Prepare a conidial suspension of Aspergillus oryzae. 5) Take 135 μL of spore suspension and 135 μL of EHA105 bacterial solution, mix them evenly, and spread them on a solid induction medium covered with a microporous filter membrane. Acetosyringone has been added to the induction medium. Cultivate at 28°C for 3 days. 6) Remove the microporous filter membrane and spread it on a Cha's medium containing hygromycin B and cephalosporin for antibiotic screening and culture at 30°C for 3 days. 7) Remove the microporous filter membrane and continue to culture until resistant colonies grow. Transfer the selected resistant colonies to another selection medium and continue screening and culture. The selected resistant transformants are verified by genomic PCR.
[0146] Expression of mature polypeptide mutants D3 and D10 (amino acid sequences are shown in SEQ ID NO:3 and SEQ ID NO:10, respectively): The constructed Aspergillus oryzae engineering bacteria were activated and cultured at 30°C for 3 days, spores were washed with sterile water, and a bacterial suspension was prepared for inoculation. Different strains were inoculated into solid fermentation medium at 2%, and further, the induction expression medium was used to culture for 6 days at 30°C and 200 rpm, and the supernatant was collected and concentrated using a 10 kDa ultrafiltration membrane to obtain mature polypeptide mutants AO-D3 and AO-D10, respectively.
[0147] AO-D3 and AO-D10 were used for enzyme catalysis, and their abilities of catalyzing the synthesis of LNT and LNnT were measured.
[0148] Specifically, 128 mM lactose, 20 mM lactose-N-triose (Lacto-N-trioseⅡ, LNTII), 0.3 mg / mL mature polypeptide mutant AO-D3 or AO-D10, 10 mmol / L MgCl2, 100 mM phosphate buffer (pH 8) were fixed to 5 mL, mixed, reacted at 40°C for 24 hours, terminated the reaction, and purified by gel column method. The results are recorded in Table 6.
[0149] Table 6
[0150]
[0151] The above description is only an embodiment of the present invention. All equivalent changes and modifications made according to the scope of the patent application of the present invention, as well as the research and selection of process parameters such as the temperature of the catalytic reaction, the amount of enzyme added, the reaction time, and the pH value, shall fall within the scope of the present invention.
Claims
1. A mature polypeptide having the activity of synthesizing lactose-N-tetraose (LNT) and lactose-N-neotetraose (LNnT), wherein the amino acid sequence is shown in SEQ ID NO:
1.
2. A mature polypeptide mutant, characterized in that: As shown in SEQ ID NO: 1, one or more amino residues at positions 182-189, 408-413, 449-454, 481-492, 561-569, 571-573, 593, 591-597, 599-606, etc. in the mature polypeptide are modified and transformed to obtain the mature polypeptide mutant, which has improved catalytic synthesis of LNT and LNnT activity; The mutant is preferably a mutant in which the amino acid residues at positions 182-185 are replaced by QPSS to GMNC, the amino acid residue at position 189 is replaced by S to T, and the amino acid residues at positions 408-412 are replaced by QSKKP to YGHYQ, and the amino acid sequence thereof is shown in SEQ ID NO: 2; The mutant is preferably a mutant in which the amino acid residues at positions 408-413 are replaced by QSKKPY to PMNRLT, the mutant is preferably a mutant in which the amino acid residues at positions 481-482 are replaced by ED to DN, and the amino acid residues at positions 484-492 are replaced by TRGDKVNVT to IKANWNESN, and the amino acid sequence thereof is shown in SEQ ID NO: 3; The mutant is preferably a mutant in which the amino acid residues at positions 450-454 are replaced by YDTTN to KNKET, the amino acid residues at positions 567-569 are replaced by DYV to SLG, and the amino acid residues at positions 571-573 are replaced by WGR to FAK, and the amino acid sequence is shown in SEQ ID NO: 4; The mutant is preferably one in which the amino acid residues at positions 182-184 are replaced by QPS to RAD, the amino acid residue at position 189 is replaced by S to T, the amino acid residues at positions 408-413 are replaced by QSKKPY to PMNRLT, the amino acid residue at position 593 is replaced by I to V, the amino acid residue at position 600 is replaced by I to L, and the amino acid residue at position 606 is replaced by Y to W, and its amino acid sequence is shown in SEQ ID NO:5; The mutant is preferably a mutant in which the amino acid residues at positions 182-184 are replaced by QPS to RAD, the amino acid residue at position 189 is replaced by S to T, the amino acid residues at positions 408-413 are replaced by QSKKPY to PMNRLT, the amino acid residues at positions 449-453 are replaced by IYDTT to SGHGA, the amino acid residue at position 593 is replaced by I to V, the amino acid residue at position 600 is replaced by I to L, and the amino acid residue at position 606 is replaced by Y to W, and its amino acid sequence is shown in SEQ ID NO:6; The mutant is preferably a mutant in which the amino acid residues at positions 182-185 are replaced by QPSS to GMNC, the amino acid residue at position 189 is replaced by S to T, the amino acid residues at positions 408-412 are replaced by QSKKP to YGHYQ, the amino acid residues at positions 481-482 are replaced by ED to DN, the amino acid residues at positions 484-492 are replaced by TRGDKVNVT to IKANWNESN, the amino acid residues at positions 567-568 are replaced by DY to SA, the amino acid residue at position 573 is replaced by R to A, the amino acid residue at position 593 is replaced by I to V, the amino acid residues at positions 595-597 are replaced by TGF to DWV, and the amino acid residues at positions 599-606 are replaced by YIGEPTPY to QSLIKYDE, and the amino acid sequence is shown in SEQ ID NO: 7; The mutant is preferably a mutant in which the amino acid residues at positions 182-185 are replaced by QPSS to GMNC, the amino acid residue at position 189 is replaced by S to T, the amino acid residues at positions 408-413 are replaced by QSKKPY to PMNRLT, the amino acid residues at positions 450-454 are replaced by YDTTN to KNKET, the amino acid residues at positions 567-569 are replaced by DYV to SLG, and the amino acid residues at positions 571-573 are replaced by WGR to FAK, and the amino acid sequence is shown in SEQ ID NO: 8; The mutant is preferably a mutant in which the amino acid residues at positions 450-454 are replaced by YDTTN to KNKET, the amino acid residue at position 481 is replaced by E to A, the amino acid residue at position 484 is replaced by T to F, the amino acid residues at positions 486-492 are replaced by GDKVNVT to FGNGSGG, the amino acid residues at positions 567-569 are replaced by DYV to SLG, the amino acid residues at positions 571-573 are replaced by WGR to FAK, the amino acid residue at position 593 is replaced by I to V, the amino acid residues at positions 595-597 are replaced by TGF to DWV, and the amino acid residues at positions 599-606 are replaced by YIGEPTPY to QSLIKYDE, and the amino acid sequence is shown in SEQ ID NO: 9; The mutant is preferably a mutant in which the amino acid residues at positions 182-184 are replaced by QPS to RAD, the amino acid residue at position 189 is replaced by S to T, the amino acid residues at positions 449-453 are replaced by IYDTT to SGHGA, the amino acid residue at position 481 is replaced by E to A, the amino acid residue at position 484 is replaced by T to F, the amino acid residues at positions 486-492 are replaced by GDKVNVT to FGNGSGG, the amino acid residues at positions 567-568 are replaced by DY to SA, the amino acid residue at position 573 is replaced by R to A, the amino acid residue at position 593 is replaced by I to V, the amino acid residues at positions 595-597 are replaced by TGF to DWV, and the amino acid residues at positions 599-606 are replaced by YIGEPTPY to QSLIKYDE, and the amino acid sequence is shown in SEQ ID NO: 10; The mutant is preferably a mutant in which the amino acid residues at positions 182-185 are replaced by QPSS to GMNC, the amino acid residue at position 189 is replaced by S to T, the amino acid residues at positions 408-413 are replaced by QSKKPY to PMNRLT, the amino acid residues at positions 449-453 are replaced by IYDTT to SGHGA, the amino acid residue at position 481 is replaced by E to A, the amino acid residue at position 484 is replaced by T to F, the amino acid residues at positions 486-492 are replaced by GDKVNVT to FGNGSGG, the amino acid residues at positions 567-568 are replaced by DY to SA, the amino acid residue at position 573 is replaced by R to A, the amino acid residue at position 593 is replaced by I to V, the amino acid residues at positions 595-597 are replaced by TGF to DWV, the amino acid residues at positions 599-606 are replaced by YIGEPTPY to QSLIKYDE, and the amino acid sequence is as shown in SEQ ID Shown in NO:
11.
3. A polynucleotide encoding the mature polypeptide or mature polypeptide mutant according to any one of claims 1 to 2.
4. A nucleic acid construct comprising the polynucleotide of claim 3 and one or more regulatory sequences operably linked thereto.
5. An expression vector comprising the polynucleotide according to claim 3, or comprising the nucleic acid construct according to claim 4.
6. A transformed host cell comprising the transformed nucleic acid construct according to claim 4 or the expression vector according to claim 5.
7. An enzyme agent or enzyme composition comprising the mature polypeptide mutant according to claim 2 according to claim 1.
8. The method for expressing the mature polypeptide and / or the mature polypeptide mutant according to any one of claims 1 to 2, comprising the following steps: (a) culturing a host cell under conditions suitable for expressing the mature polypeptide and / or mature polypeptide mutant; and (b) recovering the mature polypeptide and / or the mature polypeptide mutant; In the step (a), preferably, a host cell comprising a nucleic acid construct is cultured under conditions conducive to the production of the polypeptide, wherein the nucleic acid construct comprises a nucleotide sequence encoding the polypeptide; In the step (a), preferably, a recombinant plasmid encoding the above-mentioned mature polypeptide and / or mature polypeptide mutant gene is first constructed and then introduced into a host cell; The host cell in step (a) preferably comprises a recombinant engineered strain of a host cell; The step (b), preferably, further comprises separating and purifying the mature polypeptide and / or mature polypeptide mutant; The step (b) preferably comprises: After the expression is completed, the cultured cells are broken to obtain a crude enzyme solution containing the polypeptide; optionally, the method further includes a step of separating and purifying the polypeptide. The host cell preferably includes: Bacillus and Escherichia; further preferably includes: Escherichia coli, Escherichia hermanii, Escherichia fergusonii, Bacillus mycoides, Bacillus cereus, Bacillus licheniformis, Bacillus brevis, Bacillus circulans or Bacillus subtilis; Further preferably, the host cell is Bacillus circulans or Bacillus subtilis or Bacillus licheniformis; The mold preferably includes: Aspergillus, Trichoderma; more preferably, Trichoderma viride. viride), Trichoderma reesei, Aspergillus oryzae, Aspergillus fumigatu, Aspergillus niger, or Aspergillus flavus cells; further preferably, the host cell is an Aspergillus oryzae cell; The yeast cells preferably include cells of the genus Candida, Hansenula, Kluyveromyces, Pichia, Saccharomyces, Schizosaccharomyces, or Yarrowia; more preferably, cells of Saccharomyces cerevisiae. cerevisiae), Kluyveromyces lactis, Kluyveromyces marxianus marxinus, Yarrowia lipolytica, Rhodotorula graminis, Saccharomyces pastorianus, etc.; more preferably, Saccharomyces cerevisiae (Saccharomyces cerevisiae), Kluyveromyces lactis, Kluyveromyces marxianus marxinus) cells; In the method for expressing the mature polypeptide and / or the mature polypeptide mutant, the host cell includes a wild strain isolated from nature, a mutant strain after physical and chemical mutagenesis, or an engineered bacterium after genetic engineering.
9. Use of the mature polypeptide or mutant thereof according to any one of claims 1 to 2 in the synthesis of LNT and LNnT; In the application, preferably, the reaction substrate is a carbohydrate of lactose or its derivatives; In the application, preferably, the reaction substrates are lactose and lactose-N-triose (Lacto-N-triose, LNTII); In the application, preferably, the reaction solvent is an aqueous solvent or a solution containing solids.
